Medocaine

Lidocaine, the active ingredient in Medocaine, is a local anesthetic presented as a solution for epidural, infiltration and intraarticular use. It provides reversible loss of sensation in targeted tissues, facilitating pain‑free surgical and diagnostic procedures in adult patients and is approved for use throughout the European Union.\n\nGNH India supplies Medocaine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Medocaine is a lidocaine‑based local anesthetic used in procedures that require regional nerve blockade.\n\n- Epidural anesthesia: provides analgesia for labor, surgery, or chronic pain management by numbing spinal nerves.\n- Infiltration anesthesia: numbs superficial tissues for minor surgical or dental procedures.\n- Intraarticular anesthesia: relieves pain during joint injections or arthroscopic surgeries.

Lidocaine may cause a range of adverse reactions, from mild to severe, depending on dose and administration site.\n\nCommon Side Effects:\n- Burning or tingling at the injection site.\n- Mild hypotension or dizziness.\n- Nausea or mild headache.\n- Local swelling or erythema.\n\nSerious or Rare Side Effects:\n- Central nervous system toxicity such as seizures or loss of consciousness.\n- Cardiac arrhythmias, including ventricular tachycardia or cardiac arrest.\n- Severe allergic reactions or anaphylaxis, presenting with rash, bronchospasm, or hypotension.

When using Medocaine, clinicians should observe several safety measures to minimise risk.\n\n- Assess patient allergy: confirm no known hypersensitivity to amide‑type local anesthetics.\n- Monitor cardiac status: observe for arrhythmias during high‑dose epidural use.\n- Check liver function: lidocaine is hepatically metabolised, adjust in hepatic impairment.\n- Avoid concurrent use with other sodium channel blockers: may increase toxicity risk.\n- Store below 25°C: keep in the original container, protect from moisture and light.

Lidocaine can interact with other medicines, altering its safety profile or effectiveness.\n\nMajor Interactions (Avoid):\n- Class I antiarrhythmics (e.g., quinidine, procainamide) – may potentiate cardiotoxicity.\n- Amiodarone – increases plasma lidocaine levels, raising toxicity risk.\n- Cimetidine – reduces hepatic clearance, leading to higher systemic exposure.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blockers – may enhance hypotensive effects when combined with epidural lidocaine.\n- CNS depressants (e.g., benzodiazepines, opioids) – require monitoring for additive sedation or respiratory depression.